Headquartered in Connaught House, Dublin Fiscal year ends December NASDAQ: ALKS alkermes.com
Alkermes plc is a global biopharmaceutical company focused on neuroscience. It sells proprietary commercial products for alcohol and opioid dependence (VIVITROL), schizophrenia (ARISTADA and ARISTADA INITIO), schizophrenia and bipolar I disorder (LYBALVI), and narcolepsy (LUMRYZ). LUMRYZ is a once-nightly sodium oxybate added through the February 2026 acquisition of Avadel Pharmaceuticals. Alkermes also earns manufacturing and royalty revenue from partnered products. These include Biogen's VUMERITY and Johnson & Johnson's long-acting paliperidone franchise (XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI). Its R&D centers on a portfolio of investigational orexin 2 receptor agonists. Target indications include narcolepsy, idiopathic hypersomnia, ADHD, major depressive disorder, and fatigue associated with multiple sclerosis and Parkinson's disease. The company runs R&D operations in Massachusetts and a manufacturing facility in Ohio, and it took on significant long-term debt to fund the Avadel acquisition. Updated
The earnings miss came from $29.8 million of Avadel deal costs, while revenue topped expectations and newly acquired LUMRYZ contributed in its first full quarter. Management reiterated full-year revenue guidance, with orexin data readouts queued up over the next year.
A former Pentagon undersecretary just disclosed 57 trades in one filing, with the heaviest buying in semiconductors and electronics manufacturing: NXP, ON Semiconductor and Benchmark Electronics all picked up in size. The disclosure landed 39 days after the earliest trade.
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week, with the Federal 4th of July holiday scheduled for Friday, before we celebrate the 250th…
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Pre-Market Stock Futures: Futures are trading higher this morning after a dreadful day to start the trading week. Various reasons were cited for the risk-off bias on Monday, but the tariff situation,…
Wednesday's top analyst upgrades and downgrades included Ally Financial, Applied Materials, CrowdStrike, Fidelity National Information Services, First Solar, Fortinet, Newmont, Occidental Petroleum, Palo Alto Networks, Take-Two Interactive Software, Trade Desk, Twilio and…
Thursday's additional analyst upgrades and downgrades were on Alkermes, Altice USA, Fisker, Freshpet, Lincoln National, Maravai LifeSciences and more.
Friday’s additional top analyst upgrades and downgrades were on Alkermes, AppLovin, Delta Air Lines, Micron Technology, Stanley Black & Decker and more.
Wednesday’s top analyst upgrades and downgrades included Apple, Carvana, Elanco Animal Health, Gilead Sciences, Home Depot, Park Hotels & Resorts, Shoals Technologies, SNDL, SITE Centers and UDR.
Friday’s additional top analyst upgrades and downgrades included Alkermes, Callaway Golf, Canadian National Railway, Electronic Arts, Kroger and Union Pacific.
Thursday's top analyst upgrades and downgrades included Bed Bath & Beyond, Block, Citizens Financial, DoorDash, Exelon, Exxon Mobil, Halliburton, Kinross Gold, Lockheed Martin, Matador Resources, Mosaic, PagSeguro Digital, Peloton Interactive, Pinterest, Southwestern…
Thursday afternoon's top analyst upgrades and downgrades included Equifax, Corning, Iridium Communications, KB Home and Tesla.
Wednesday’s top analyst upgrades and downgrades included Beyond Meat, Capital One, Decker's Outdoors, Diageo, DoorDash, Foot Locker, Krispy Kreme, MP Materials, Redbox Entertainment, Shift4 Payments, Tronox, and Urban Outfitters.
Thursday's top analyst upgrades and downgrades included AT&T, Alibaba, Ally Financial, BioMarin Pharmaceutical, Box, Citrix Systems, Nio, Schlumberger and TJX Companies.
Thursday’s top analyst upgrades and downgrades included Advanced Micro Devices, Alkermes, Clover Health, Okta, Peloton Interactive, Starbucks and Unilever.
Thursday's top analyst upgrades and downgrades included Alkermes, Amazon.com, Citigroup, eBay, Fastly, Groupon, Lyft, Netflix, ONEOK, Roku, Uber Technologies and Zoom Video Communications.
Friday's top analyst upgrades, downgrades and initiations included Alkermes, Aurora Cannabis, BlackRock, Duke Energy, Nvidia, Ralph Lauren, SunPower, Veeva Systems and Yelp.
Alkermes plc is a global biopharmaceutical company focused on neuroscience. It sells proprietary commercial products for alcohol and opioid dependence (VIVITROL), schizophrenia (ARISTADA and ARISTADA INITIO), schizophrenia and bipolar I disorder (LYBALVI), and narcolepsy (LUMRYZ).
24/7 Wall St.'s 12-month price target for ALKS is $41.81, rated Hold. The Wall Street consensus target is $56.21. ALKS price prediction →
